Oxford Cancer Analytics, an Oxford, UK- and Toronto, Canada-based medtech firm creating blood assessments for early most cancers detection utilizing proteomics and AI, raised USD$11M in Collection A funding.
The spherical was led by We Enterprise Capital and Cross-Border Affect Ventures with participation from return traders Eka Ventures, and Civilization Ventures, and new traders DigitalDx Ventures, Macmillan Most cancers Assist, Aurelium Ventures, OKG Capital, and angel traders.
The corporate intends to make use of the funds to develop and globally commercialize its new technology of minimally invasive liquid biopsy blood assessments for the early detection of lung most cancers.
Oxford Most cancers Analytics (OXcan) is creating a brand new technology of liquid biopsy blood assessments utilizing proteomics and explainable machine studying approaches that may detect the deadliest cancers early, once they can nonetheless be cured.
This blood check might be carried out in a minimally invasive, and routine method with superior accuracy and localization capability in massive populations. The corporate has utilized their biomarker discovery and validation platform ranging from lung most cancers, the main reason for most cancers mortality worldwide, and achieved ISO13485 certification standing.
OXcan has additionally appointed Dr. Heinrich Roder as Senior Vice President, Analysis & Growth.
FinSMEs
09/01/2025
